Photo by nci from unsplash
A recent report published in Cancer Cell used elaborate in vitro and in vivo systems to link FTO expression to the pathogenesis of acute myeloid leukemia (AML) (Li et al.,… Click to show full abstract
A recent report published in Cancer Cell used elaborate in vitro and in vivo systems to link FTO expression to the pathogenesis of acute myeloid leukemia (AML) (Li et al., 2017). The N6-methyladenosine (m6A) RNA demethylase encoded by FTO is an α-ketoglutarate (α-KG)-dependent dioxygenase (Fedeles et al., 2015). α-KG-dependent dioxygenases are competitively inhibited by the structurally related metabolite D-2-hydorxyglutarate (D2-HG), which aberrantly accumulates in isocitrate dehydrogenase 1 or 2 (IDH1/2)-mutant tumors, including ∼20% of AMLs (Cairns and Mak, 2013).
Journal Title: Cancer cell
Year Published: 2017
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!